BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?

BMO (NYSE: BMO) Capital Markets has been quite bullish about BioNTech SE (NASDAQ: BNTX) this year. However, that's no longer the case.

On Sept. 8, 2026, BioNTech's shares dipped after BMO downgraded the biotech stock from an "outperform" rating to a "market perform" rating. BMO also lowered its 12-month price target for BioNTech from $128 to $105.

There's a simple explanation for BMO's new take on BioNTech. But is Wall Street underestimating the company's cancer pipeline?

Image source: Getty Images.

What the downgrade got right -- and wrong

It isn't all that surprising that BMO Capital Markets is now significantly less optimistic about BioNTech's near-term prospects than it once was. The global demand for BioNTech's COVID-19 vaccines continues to wane.

BMO's downgrade also followed a key setback in BioNTech's pipeline. On Aug. 28, 2026, the company announced that it was canceling a Phase 2 clinical trial evaluating the personalized mRNA cancer vaccine BNT122-01 for the treatment of colorectal cancer. There weren't any safety concerns, but the experimental therapy didn't demonstrate statistically significant efficacy. As a result of the bad news, the company lowered its full-year revenue guidance to €1.6 billion to €1.9 billion from its previous forecast of €2 billion to €2.3 billion.

Investors were excited about BioNTech after Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) reported positive results from a late-stage study of Moderna's personalized mRNA cancer vaccine intismeran autogene, in combination with Merck's blockbuster immunotherapy Keytruda. However, the momentum has now nearly evaporated.

But the rest of BioNTech's oncology pipeline shouldn't be ignored. The company has over 25 Phase 2 and Phase 3 clinical studies evaluating experimental cancer therapies underway. It recently announced encouraging results from one of them, with gotistobart nearly doubling median overall survival compared with standard-of-care chemotherapy in previously treated patients with squamous non-small cell lung cancer (NSCLC).

BioNTech expects to report data from 11 other late-stage clinical studies by the end of 2029. These trials focus on multiple types of tumors, including breast cancer, gastrointestinal cancer, and lung cancer. Data from three studies will be announced before the end of this year.

A biotech stock that's still worth buying

Meanwhile, BioNTech's market cap hovers around $24 billion. As of June 30, 2026, the company's cash, cash equivalents, and security investments totaled roughly €16.6 billion (around $19 billion). This arguably puts BioNTech in value stock territory.

Yes, BioNTech has experienced a big clinical setback and cut its full-year guidance. On the surface, the stock might seem to deserve a downgrade. However, investing in BioNTech right now amounts to getting a robust pipeline essentially for free. This biotech stock is still worth buying, in my view.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se, Merck, and Moderna. The Motley Fool has a disclosure policy.